These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37066909)

  • 1. Partial Least Squares Regression Analysis of Alzheimer's Disease Biomarkers, Modifiable Health Variables, and Cognitive Change in Older Adults with Mild Cognitive Impairment.
    Stark J; Hiersche KJ; Yu JC; Hasselbach AN; Abdi H; Hayes SM;
    J Alzheimers Dis; 2023; 93(2):633-651. PubMed ID: 37066909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial Least Squares Analysis of Alzheimer's Disease Biomarkers, Modifiable Health Variables, and Cognition in Older Adults with Mild Cognitive Impairment.
    Stark J; Palombo DJ; Hayes JP; Hiersche KJ; Hasselbach AN; Hayes SM;
    J Int Neuropsychol Soc; 2022 Sep; 28(8):781-789. PubMed ID: 34664547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults.
    Schaeverbeke JM; Gabel S; Meersmans K; Luckett ES; De Meyer S; Adamczuk K; Nelissen N; Goovaerts V; Radwan A; Sunaert S; Dupont P; Van Laere K; Vandenberghe R
    Alzheimers Res Ther; 2021 Apr; 13(1):75. PubMed ID: 33827690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
    Hohman TJ; Bell SP; Jefferson AL;
    JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifactorial Modeling of Cognitive Trajectories Using an Advanced Regression Technique: Improving Our Understanding of Biomarkers and Modifiable Variables that Support Cognition.
    Fletcher E
    J Alzheimers Dis; 2023; 93(2):815-819. PubMed ID: 37212065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing forgetfulness: can episodic-memory tests predict early Alzheimer's disease?
    Warren SL; Moustafa AA; Alashwal H;
    Exp Brain Res; 2021 Sep; 239(9):2925-2937. PubMed ID: 34313791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study.
    Cumplido-Mayoral I; Brugulat-Serrat A; Sánchez-Benavides G; González-Escalante A; Anastasi F; Milà-Alomà M; López-Martos D; Akinci M; Falcón C; Shekari M; Cacciaglia R; Arenaza-Urquijo EM; Minguillón C; Fauria K; Molinuevo JL; Suárez-Calvet M; Grau-Rivera O; Vilaplana V; Gispert JD;
    Lancet Healthy Longev; 2024 Apr; 5(4):e276-e286. PubMed ID: 38555920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease.
    Giorgio J; Landau SM; Jagust WJ; Tino P; Kourtzi Z;
    Neuroimage Clin; 2020; 26():102199. PubMed ID: 32106025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
    Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
    JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline.
    Hohman TJ; Tommet D; Marks S; Contreras J; Jones R; Mungas D;
    Neurobiol Aging; 2017 Oct; 58():120-128. PubMed ID: 28732249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
    Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P
    Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild behavioral impairment as a predictor of cognitive functioning in older adults.
    Rouse HJ; Small BJ; Schinka JA; Loewenstein DA; Duara R; Potter H
    Int Psychogeriatr; 2021 Mar; 33(3):285-293. PubMed ID: 32456733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions.
    Teitsdottir UD; Jonsdottir MK; Lund SH; Darreh-Shori T; Snaedal J; Petersen PH
    Alzheimers Res Ther; 2020 Aug; 12(1):92. PubMed ID: 32753068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.